Human Papillomavirus Vaccine Therapy in Treating Men With HIV-1 Infection
NCT00513526
Completed
RATIONALE: Vaccines made from human papillomavirus may help the body build an effective immune response to kill HIV cells. PURPOSE: This phase II trial is studying the side effects and how well human papillomavirus vaccine therapy works in treating men with HIV-1 infection.
Gender:
MALE
Ages:
18 years and above
Trial Updated:
10/27/2023
Locations: UCLA Clinical AIDS Research and Education (CARE) Center, Los Angeles, California +7 locations
Conditions: Infection, Precancerous Condition
Register for Updates
A Study of mRNA-1010 Seasonal Influenza Vaccine in Healthy Adults
NCT04956575
Completed
The study comprises 3 parts: Phase 1/2, Phase 2 Northern Hemisphere (NH), and Phase 2 extension. The primary objective of this study is to evaluate the safety, reactogenicity, and humoral immunogenicity of mRNA-1010 vaccine.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/25/2023
Locations: Cognitive Clinical Trials - Phoenix, Phoenix, Arizona +20 locations
Conditions: Seasonal Influenza
Register for Updates
A Study on the Immune Response and Safety of the Shingles Vaccine and the Influenza Vaccine When Either is Given to Healthy Adults at the Same Time or Following a COVID-19 Booster Vaccine
NCT05047770
Completed
The aim of this study was to evaluate the immune response and safety of both GlaxoSmithKline Biologicals SA's (GSK's) herpes zoster (HZ) subunit (su) vaccine in healthy adults 50 years of age (YOA) and older and quadrivalent seasonal influenza (Flu D-QIV) vaccine in healthy adults 18 YOA and older, when administered sequentially or co-administered with Moderna's mRNA-1273 booster vaccination against COVID-19.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/19/2023
Locations: GSK Investigational Site, Tempe, Arizona +45 locations
Conditions: Herpes Zoster
Register for Updates
COVID-19 Breakthrough Infection in Fully Vaccinated People and in People Who Received a Booster Dose
NCT05392075
Completed
A novel coronavirus, SARS-CoV-2 (formerly known as the 2019 novel coronavirus \[2019-nCoV\]) was identified as the agent that caused an outbreak of pneumonia (termed COVID-19) in Wuhan, China in December 2019. The virus quickly spread to other countries and on March 11, 2020, the World Health Organization (WHO) declared COVID-19 a pandemic. By March 2021, many nations and organizations embarked on finding a cure or vaccine for this devastating viral infection. The Pfizer COVID-19 mRNA vaccine wa... Read More
Gender:
ALL
Ages:
Between 18 years and 100 years
Trial Updated:
10/18/2023
Locations: Methodist Dallas Medical Center, Dallas, Texas
Conditions: COVID-19 Pneumonia, COVID-19
Register for Updates
Vaccine Therapy in Patients With Stage II, III, or IV Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer
NCT00112957
Completed
This was a Phase 2, single-center, open-label study of recombinant vaccinia-NY-ESO-1 (rV-NY-ESO-1) and recombinant fowlpox-NY-ESO-1 (rF-NY-ESO-1) injections in patients who had a complete response to standard therapy for epithelial ovarian, fallopian tube, or primary peritoneal carcinoma and whose tumors expressed NY-ESO-1 or LAGE-1 antigen. Study objectives were to evaluate maintenance of remission at 12 months, time to failure of vaccine therapy, cellular and humoral immunity and any correlati... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
10/02/2023
Locations: Roswell Park Cancer Institute, Buffalo, New York
Conditions: Fallopian Tube Cancer, Ovarian Cancer, Peritoneal Cavity Cancer
Register for Updates
PVSRIPO for Recurrent Glioblastoma (GBM)
NCT01491893
Completed
Purpose of the Study: To determine the maximally tolerated dose (MTD) and the Recommended Phase 2 Dose (RP2D) of PVSRIPO when delivered intracerebrally by convection-enhanced delivery (CED). To obtain correlative mechanistic evidence of PVSRIPO's effects on infected WHO Grade IV malignant glioma tumors and to estimate progression-free survival (PFS) and overall survival (OS) in recurrent WHO Grade IV malignant glioma patients. To obtain information about clinical response rates to intratumoral... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/26/2023
Locations: Duke University Medical Center, Durham, North Carolina
Conditions: GBM, Glioblastoma, Glioma, Malignant Glioma
Register for Updates
Collection of Serum Samples From Children and Older Adults Receiving the 2019-2020 Formulations of Fluzone® Quadrivalent and Fluzone® High-Dose Influenza Vaccines, Respectively
NCT04109222
Completed
The primary objective of the study was to provide sera (collected from participants before vaccination \[Blood Sample 1\] and after final vaccination \[Blood Sample 2\]) to the Center for Biologics Evaluation and Research (CBER) for further analysis by the World Health Organization (WHO), the Centers for Disease Control and Prevention (CDC), and the Food and Drug Administration (FDA) to support formulation recommendations for subsequent influenza vaccines.
Gender:
ALL
Ages:
Between 6 months and 83 years
Trial Updated:
09/26/2023
Locations: Investigational Site Number 8400002, Bardstown, Kentucky +1 locations
Conditions: Influenza
Register for Updates
Annual Study for Collection of Serum Samples in Children and Older Adults Receiving the 2020-2021 Formulations of Fluzone Quadrivalent Vaccine and Fluzone High-Dose Quadrivalent Vaccine, Respectively
NCT04551677
Completed
Primary Objective: To provide serum samples (collected from participants before vaccination \[Blood Sample 1\] and after final vaccination \[Blood Sample 2\]) to Center for Biologics Evaluation and Research (CBER) for further analysis by the World Health Organization (WHO), Centers for Disease Control and Prevention (CDC), and Food and Drug Administration (FDA) to support formulation recommendations for subsequent influenza vaccines. In addition, serum samples from adult participants may be fur... Read More
Gender:
ALL
Ages:
Between 6 months and 84 years
Trial Updated:
09/26/2023
Locations: Investigational Site Number 8400001, Bardstown, Kentucky +1 locations
Conditions: Influenza Immunization, Healthy Volunteers
Register for Updates
Annual Study for Collection of Serum Samples in Children and Older Adults Receiving the 2021-2022 Formulations of Fluzone Quadrivalent Vaccine and Fluzone High-Dose Quadrivalent Vaccine, Respectively
NCT05050318
Completed
This was a phase IV, multi-center, open-label study. The study collected serum samples from children 6 months to less than (\<) 9 years of age who received Fluzone Quadrivalent vaccine and adults greater than or equal to (\>=) 65 years of age who received Fluzone High-Dose Quadrivalent vaccine for submission to CBER to aid in the influenza vaccine strain selection process.
Gender:
ALL
Ages:
6 months and above
Trial Updated:
09/26/2023
Locations: Investigational Site Number :8400001, Bardstown, Kentucky +1 locations
Conditions: Influenza Immunization, Healthy Volunteers
Register for Updates
Study of a Quadrivalent High-Dose Influenza Vaccine and a Moderna COVID-19 Vaccine Administered Either Concomitantly or Singly in Participants 65 Years of Age and Older Previously Vaccinated With a 2-dose Schedule of Moderna COVID-19 Vaccine
NCT04969276
Completed
The main purpose of this Phase II study was to assess the safety and immunogenicity of a dose of Fluzone High-Dose (HD) Quadrivalent vaccine and a third dose or booster dose of Moderna coronavirus disease 19 (COVID-19) vaccine administered concomitantly or singly in adults 65 years of age and older having received their second dose of the 2-dose schedule of Moderna COVID-19 vaccine at least 5 months before enrollment in the study.
Gender:
ALL
Ages:
65 years and above
Trial Updated:
09/26/2023
Locations: Investigational Site Number :8400003, Glendale, Arizona +5 locations
Conditions: Influenza Immunization, Healthy Volunteers
Register for Updates
The Safety of Administering a Second Dose of a COVID-19 mRNA Vaccine in Individuals Who Experienced a Systemic Allergic Reaction to an Initial Dose
NCT04977479
Completed
Background: Some people have allergic reactions to COVID-19 mRNA vaccines. Researchers want to learn more about these reactions to provide guidance on who can safely receive the vaccines, including a second dose in people who had a reaction to the first. Objective: To study the safety of giving a second mRNA COVID-19 vaccine dose to people who had a systemic allergic reaction to their first dose. Eligibility: People aged 16-69 who had a systemic allergic reaction to their first dose of COVI... Read More
Gender:
ALL
Ages:
Between 16 years and 69 years
Trial Updated:
09/21/2023
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Systemic Allergic Reaction
Register for Updates
Salmonella Conjugates CVD 2000: Study of Responses to Vaccination With Trivalent Salmonella Conjugate Vaccine to Prevent Invasive Salmonella Disease
NCT05525546
Completed
This is a randomized, placebo-controlled interventional study. The main purpose of this research is to test the safety and measure the immune response of the trivalent vaccine against invasive Salmonella disease. The vaccine will be tested over a range of doses.
Gender:
ALL
Ages:
Between 18 years and 49 years
Trial Updated:
09/18/2023
Locations: Pharmaron, Baltimore, Maryland
Conditions: Risk Reduction
Register for Updates